跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DO-24
首页
药物
DO-24
DO-24
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Carbonyl-multi-boron nitrogen derivative and application thereof
申请人: SUZHOU SICUI NEW ENERGY PHOTOELECTRIC TECH RESEARCH INSTITUTE CO LTD
优先权: 2025
CN
Method for establishing rat contrast-induced nephropathy model
申请人: FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV
优先权: 2019
CN
MIFEPRISTONE FOR USE IN IMPROVING INSULIN SENSITIVITY
申请人: NIEMAN LYNNETTE K
优先权: 2019
EP
US
WO
5 件公开
Composition with skin whitening function
申请人: GU LI BIOTECHNOLOGY CO LTD
优先权: 2012
CN
MULTISPECIFIC ANTIBODIES
申请人: ABIDEA INC
优先权: 2025
US
Hypertensive healthcare drug pillow
申请人: SHANDONG ZHONGDA PHARM CO LTD
优先权: 2013
CN
Chinese herbal medicine compound preparation and preparation method for treating anemia caused by qi-blood deficiency
申请人: TIANJIN SHANJI HONGXING TECH DEVELOPMENT CO LTD
优先权: 2017
CN
Methylnaltrexone bromide injection tolerant to terminal sterilization and preparation method of methylnaltrexone bromide injection
申请人: BEIJING HUAYAO KECHUANG PHARMACEUTICAL TECH DEVELOPMENT CO LTD
优先权: 2025
CN
药物
反馈